Oxford spinout grabs $9M A round for peptide platform; bluebird gets a 'breakthrough' at the FDA
→ An Oxford spinout has nabbed about $9 million in a Series A round designed to allow the university founders to industrialize their peptide …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
